Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Sold by Squarepoint Ops LLC

Squarepoint Ops LLC lowered its stake in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) by 23.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 75,929 shares of the biopharmaceutical company’s stock after selling 23,318 shares during the period. Squarepoint Ops LLC owned 0.15% of Puma Biotechnology worth $232,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of PBYI. Acorn Capital Advisors LLC acquired a new position in shares of Puma Biotechnology during the 4th quarter valued at about $7,475,000. Kennedy Capital Management LLC boosted its holdings in Puma Biotechnology by 36.5% in the 4th quarter. Kennedy Capital Management LLC now owns 809,375 shares of the biopharmaceutical company’s stock valued at $2,469,000 after purchasing an additional 216,329 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Puma Biotechnology by 24.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 863,760 shares of the biopharmaceutical company’s stock valued at $2,635,000 after purchasing an additional 170,968 shares during the last quarter. D. E. Shaw & Co. Inc. boosted its holdings in Puma Biotechnology by 287.9% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 222,608 shares of the biopharmaceutical company’s stock valued at $679,000 after purchasing an additional 165,220 shares during the last quarter. Finally, Two Sigma Investments LP lifted its holdings in Puma Biotechnology by 266.2% in the fourth quarter. Two Sigma Investments LP now owns 181,471 shares of the biopharmaceutical company’s stock valued at $553,000 after acquiring an additional 131,916 shares during the last quarter. Institutional investors and hedge funds own 61.29% of the company’s stock.

Puma Biotechnology Trading Up 1.9%

NASDAQ PBYI opened at $3.72 on Friday. The firm’s 50-day moving average is $3.11 and its two-hundred day moving average is $3.10. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 1.40. Puma Biotechnology, Inc. has a 12 month low of $2.23 and a 12 month high of $4.13. The stock has a market capitalization of $184.63 million, a P/E ratio of 7.75 and a beta of 1.29.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Wall Street Zen upgraded Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a report on Thursday, May 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price target on shares of Puma Biotechnology in a research note on Friday, February 28th.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.